pembrolizumab
NP01/2017/MSD3475
Phase 2 small_molecule active
Quick answer
pembrolizumab for Locally Recurrent Cancer is a Phase 2 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Locally Recurrent Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active